Press Releases
- EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS March 21, 2013 13:00 (CET)
- FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS March 6, 2013 14:00 (CET)
- Active Biotech raises SEK 270 million through a directed new issue to Investor March 6, 2013 08:30 (CET)
- Active Biotech AB Year-end report January - December 2012 February 14, 2013 08:30 (CET)
- Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer January 28, 2013 08:30 (CET)
- Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference January 3, 2013 10:00 (CET)
- Laquinimod highlights from Teva Investor Day December 11 December 12, 2012 08:30 (CET)
- Teva Investor Meeting December 11 December 11, 2012 08:30 (CET)
- Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer December 10, 2012 07:30 (CET)
- Active Biotech's election committee appointed November 15, 2012 08:30 (CET)